Chronic Lymphocytic Leukemia with Jan A. Burger, MD, PhD Case 1

The FDA updated the fludarabine phosphate injection labeling under Project Renewal, clarifying the dosage for combination therapy and streamlining safety warnings.

Current frontline treatment options for patients with chronic lymphocytic leukemia have grown over the past year, specifically with the approval of zanubrutinib.

Nicole Lamanna, MD, discussed some of the ongoing clinical trials evaluating new therapies for patients with chronic lymphocytic leukemia.

In season 4, episode 7 of Targeted Talks, Cyrus M. Khan, MD, discusses the latest FDA activity in the chronic lymphocytic leukemia space.

Cyrus M. Khan, MD, discussed recent advancements in CLL treatment, particularly the shift to nonchemotherapy options and the availability of CAR T-cell therapy.

The N-AVD regimen showed improved progression-free survival and lower toxicity than BV-AVD in advanced Hodgkin lymphoma, particularly benefiting patients 60 and older.